CMS Will Cover New Alzheimer’s Drugs with Real-World Data Registry Participation

Image from Freestock

The US Centers for Medicare and Medicaid Services (CMS) has provided more insights into coverage details regarding new therapeutics for Alzheimer’s disease. Once a drug receives approval by the Food and Drug Administration (FDA), Medicare will cover them if clinicians participate in a real-world data (RWD) registry.

According to MyChesCo, “Clinicians will be able to submit this information through a nationwide, CMS-facilitated portal. The portal will be available when any product gains traditional approval and will collect information via an easy-to-use format. This method, and any others that may follow, will adhere to robust privacy protections in accordance with applicable federal laws and regulations, including HIPAA. CMS and researchers will have access to the information to conduct studies, furthering knowledge of how these drugs can potentially help people.”

To read more, click here.

(Source: MyChesCo, June 28^th, 2023)